Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

cancers (DTC) with iodine-avid metastases. The investigators hypothesize that precise dosimetric planning will permit this combined RAI-XRT radiotherapeutic approach to be safe and permit higher tumor

  • 0 views
  • 09 Jun, 2022
  • 1 location
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Background About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective. Researchers want to see if they can better detect thyroid tumors by using a compound called 68Gallium-DOTATATE. This compound may bind to …

  • 5 views
  • 04 Oct, 2022
  • 1 location
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

FES PET/CT imaging for invasive lobular cancer

  • 0 views
  • 14 Jul, 2022
  • 1 location
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking …

high-risk neuroblastoma
dinutuximab
conventional surgery
topotecan
mycn protein
  • 117 views
  • 15 Oct, 2022
  • 105 locations
18F-DOPA II - PET Imaging Optimization

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients (less than 18 years old) with congenital hyperinsulinism. Pediatric patients (less than 18 years old) with neuroblastoma. Pediatric (less than 18 years old) or Adult patients (18 or older) with …

parkinson's disease
dementia
dopa
  • 8 views
  • 03 May, 2022
  • 1 location
'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

This is a single-arm open-label phase I/II trial studying the safety and efficacy of focal 're-priming' radiation therapy (RT) to FDG-avid residual sites of disease in relapsed/refractory non

b-cell lymphoma
diffuse large b-cell lymphoma
follicular lymphoma
refractory non-hodgkin's lymphoma
large b-cell lymphoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
Brazilian Total Neoadjuvant Therapy Trial

-radiation and no tumor can be found in the surgical specimen. These patients can be followed with close surveillance and avid surgery. The aim of this study is to evaluate if a strategy including the use of

  • 0 views
  • 27 Oct, 2021
  • 1 location
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

objective of this study is to compare the 124 I -PET/CT lesional and whole body dosimetry in each individual patient with metastatic radioiodine (RAI)-avid thyroid cancer under preparation with rhTSH and

recombinant thyroid-stimulating hormone
thyrotropin alpha
avid
thyrotropin
metastasis
  • 13 views
  • 22 Oct, 2022
  • 1 location
A Prospective Pilot Study Investigating rhPSMA 7.3 PET/MRI in Detecting Recurrent Disease and Aid in Radiotherapy Planning in Patients With Biochemically Recurrent Prostate Cancer

This prospective pilot study will assess the feasibility of rh PSMA 7.3 positron emission tomography/magnetic resonance imaging (PET/MRI) scans in detecting prostate cancer that may have come back (recurrent) in patients with increasing levels of prostate-specific antigen (PSA) following prostate surgery (biochemically recurrent). An increase in PSA levels alone does …

  • 0 views
  • 27 Oct, 2022
  • 1 location
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL) (OPTIMUM)

The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma

ejection fraction
high-risk neuroblastoma
karnofsky performance status
doxorubicin
topotecan
  • 58 views
  • 25 Oct, 2022
  • 20 locations